 Kristi S. Anseth earned her B.S. degree from Purdue University in 1992 and her Ph.D. degree from the University of Colorado in 1994. She then conducted post-doctoral research at MIT and subsequently joined the Department of Chemical and Biological Engineering at the University of Colorado at Boulder as an Assistant Professor in 1996. Dr. Anseth is presently a Howard Hughes Medical Institute Investigator and Distinguished Professor of Chemical and Biological Engineering. Her research interests lie at the interface between biology and engineering where she designs new biomaterials for applications in drug delivery and regenerative medicine. Dr. Anseth’s research group has published over 190 publications in peer-reviewed journals and presented over 170 invited lectures in the fields of biomaterials and tissue engineering. She was the first engineer to be named a Howard Hughes Medical Institute Investigator and received the Alan T. Waterman Award, the highest award of the National Science Foundation for demonstrated exceptional individual achievement in scientific or engineering research. Most recently, she was elected a member of the National Academy of Engineering and the Institute of Medicine. Dr. Anseth is also a dedicated teacher, who has received four University Awards related to her teaching, as well as the American Society for Engineering Education’s Curtis W. McGraw Award. Dr. Anseth is a Fellow of the American Association for the Advancement of Science, the American Institute for Medical and Biological Engineering, and the Materials Research Society. She also serves on the editorial boards or as associate editor of Biomacromolecules, Journal of Biomedical Materials Research — Part A, Acta Biomaterialia, and Biotechnology & Bioengineering.
 Stylianos E. Antonarakis is Professor and Chairman of the Department of Genetic Medicine and Development at the University of Geneva Medical School. His department is recognized for its active role in research, teaching and patient care. Before moving to Geneva he was a postdoctoral fellow and faculty member at Johns Hopkins University in the Department of Pediatrics and in the Center of Medical Genetics (now the McKusick-Nathans Institute of Genetic Medicine). His lab participates in many projects involving the genetics of monogenic and polygenic disorders, including Down syndrome, as well as the annotation of the human genome and particularly of human chromosome 21. He is on the editorial board of many high profile journals such as Genome Research and Genomics and has recently served as President of the European Society for Human Genetics. He has published more than 470 papers in peer-reviewed journals since 1982. He was elected to the Johns Hopkins University Society of Scholars in 2006 after being nominated by Victor McKusick, University Professor of Medical Genetics in the Department of Medicine.
 Director of the Colorado Initiative for Molecular Biotechnology; Distinguished Professor, University of Colorado-Boulder Investigator of the Howard Hughes Medical Institute Nobel Laureate Tom Cech has been on the faculty of the University of Colorado, Boulder since 1978 and holds a joint appointment at the Anschutz Medical School. In 2000, he was named president of the Howard Hughes Medical Institute and remained in this position until 2009. Currently, his lab at the University of Colorado, Boulder investigates the structure and replication of telomeric DNA. Cech shared the 1989 Nobel Prize in Chemistry for his discovery of catalytic RNA. In addition to this award, Cech has won a number of other international awards and prizes, including the Heineken Prize of the Royal Netherlands Academy of Sciences (1988), the Albert Lasker Basic Medical Research Award (1988) and the National Medal of Science (1995). Cech has been elected to the U.S. National Academy of Sciences and the Institute of Medicine and also was awarded a lifetime professorship by the American Cancer Society.
 Chairman, Founder, and CEO of SomaLogic
Founder of NeXstar and Synergen
Dr. Larry Gold is the founder, Chairman of the Board, and Chief Executive Officer of SomaLogic. During career, Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology. In addition, Dr. Gold has been a member of the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995.
 Dr. Leinwand is a Molecular, Cellular, and Developmental Biology (MCDB) Professor and Director of the Colorado Initiative in Molecular Biotechnology at the University of Colorado, Boulder. She was recruited to be Chair of MCDB in 1995. She received her Bachelor’s degree from Cornell University, her PhD from Yale University and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado. While at Albert Einstein she became a Full Professor and was Director of the Cardiovascular Research Center. Once moved to Colorado, along with Michael Bristow, she founded the intercampus University of Colorado Cardiovascular Institute which promotes research and training in cardiovascular disease. They, along with Eric Olson at the University of Texas, Southwestern Medical Center, founded Myogen, Inc. which was recently sold to Gilead Pharmaceuticals. More recently, she was a co-founder of Hiberna, Inc, a biotechnology company using pythons and hibernating ground squirrels to develop novel pharmaceuticals. Her work as a cardiac biologist is of importance to both basic scientists and clinicians. The interests of Dr. Leinwand’s laboratory are the genetics and molecular physiology of inherited diseases of the heart and how gender and diet modify the heart. The study of these diseases has required multidisciplinary approaches, involving molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of human tissues. To accomplish this, Dr. Leinwand has developed a highly collaborative group in Boulder, bringing together specialized basic scientists and clinical cardiologists. Her laboratory’s efforts are well-funded by multiple grants from the National Institutes of Health and her teaching is recognized by funding from the Howard Hughes Medical Institute’s Professor Program. She is also the Principle Investigator of the HHMI program called the Biological Sciences Initiative which supports undergraduate research, K-12 outreach and educational programs for high school teachers. Leslie served as the interim Director of the Linda Crnic Institute for Down syndrome until Dr. Ed McCabe’s appointment.
 Professor Department of Physiology Johns Hopkins University School of Medicine
Dr. Roger Reeves is Professor in the Department of Physiology and a Core Faculty Member of the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine. He earned his B.S. from Bowling Green State University in Ohio and his Ph.D. at University of Maryland, doing his thesis research at the National Cancer Institute. He began working on gene expression in Down syndrome early in his career. Recent work includes human genetic studies to identify genetic modifiers that contribute to a more or less severe presentation of Down syndrome. His laboratory is studying a possible therapeutic approach for Down syndrome features. He recently demonstrated the basis for the reduced frequency of solid tumors in people with trisomy 21. He dirests the Down Syndrome Cognition Project, a multi-site effort to employ the Arizona Cognitive Test Battery in conjunction with genetic analysis to identify genetic contributors to variable cognitive ability in DS. The DSCP network and ACTB provide a structure to recruit volunteers and monitor effectiveness of drugs designed to ameliorate cognitive dysfunction specific to people who have trisomy 21.
 Vice Chancellor for Research University of Colorado Denver Professor, School of Medicine
Richard J. Traystman, PhD, received his BS and MS degrees from Long Island University and his PhD from Johns Hopkins University Medical Center. Traystman is presently editor-in-chief of the Journal of Cerebral Blood Flow and Metabolism, and he also serves on the editorial boards of several other prestigious journals and reviews manuscripts for a multitude of journals. He has been associate editor for the heart and circulatory section of the American Journal of Physiology and was deputy editor for Critical Care Medicine. Traystman has received numerous distinguished awards from both clinical and basic science organizations for his work. He has has published more than 450 articles in peer-reviewed journals, has trained more than 100 fellows and students and has been funded by NIH throughout his career.
|
|